¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"chronic active inflammation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chronic myeloproliferative disorder
    ¸¸¼º°ñ¼öÁõ½ÄÁúȯ
  • chronic obstructive pulmonary disease
    ¸¸¼ºÆó¼âÆóÁúȯ
  • chronic pain syndrome
    ¸¸¼ºÅëÁõÁõÈıº
  • chronic persistent hepatitis
    ¸¸¼ºÁö¼Ó°£¿°
  • chronic progressive disciform granulomatosis
    ¸¸¼ºÁøÇà¿ø¹ÝÀ°¾ÆÁ¾Áõ
  • chronic relapsing pancreatitis
    ¸¸¼ºÀç¹ßÀÌÀÚ¿°, ¸¸¼ºÀç¹ßÃéÀå¿°
  • chronic renal failure
    ¸¸¼ºÄáÆÏ±â´É»ó½Ç, ¸¸¼º½ÅºÎÀü
  • chronic vasomotor instability
    ¸¸¼ºÇ÷°ü¿îµ¿ºÒ¾ÈÁ¤
  • croupous inflammation
    Å©·çÇÁ¿°Áõ
  • cytopathic-cytoproliferative inflammation
    ¼¼Æ÷º´º¯¼¼Æ÷Áõ½Ä¿°Áõ
  • catarrhal inflammation
    īŸ¸£¿°Áõ
  • diffuse inflammation
    ±¤¹üÀ§¿°Áõ
  • exudative inflammation
    »ïÃâ¿°Áõ
  • fibrinous inflammation
    ¼¶À¯¼Ò¿°Áõ, ÇǺ기¿°Áõ
  • granulomatous inflammation
    À°¾ÆÁ¾¿°Áõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • catarrhal inflammation
    īŸ¸£¿°Áõ
  • croupous inflammation
    Å©·ì¿°Áõ
  • cytopathic-cytoproliferative inflammation
    ¼¼Æ÷º´º¯¼¼Æ÷Áõ½Ä¿°Áõ
  • diffuse inflammation
    ¹Ì¸¸¿°Áõ
  • exudative inflammation
    »ïÃâ¿°Áõ
  • fibrinous inflammation
    ¼¶À¯¼Ò¿°Áõ
  • granulomatous inflammation
    À°¾ÆÁ¾¿°Áõ
  • hernial inflammation
    Ç츣´Ï¾Æ¿°
  • inflammation
    ¿°, ¿°Áõ
  • membranous inflammation
    ¸·¿°Áõ
  • metastatic inflammation
    ÀüÀÌ¿°Áõ
  • necrotizing inflammation
    ±«»ç¿°Áõ
  • obliterative inflammation
    Æó»ö¿°Áõ
  • phlegmonous inflammation
    °áÇÕÁ¶Á÷¿°Áõ
  • productive inflammation
    Áõ½Ä¿°Áõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • purulent inflammation
    È­³ó¼º ¿°Áõ(ûùÒÛàõ æúñø)
  • reactive inflammation
    ¹ÝÀÀ¼º ¿°Áõ(Úãëëàõ)
  • MR active element
    ÀÚ±â°ø¸í Ȱ¼º ¿ä¼Ò
  • MR active nuclei
    ÀÚ±â°ø¸í Ȱ¼º ÇÙ
  • active
    Ȱµ¿¼º(üÀÔÑàõ), ´Éµ¿¼º(ÒöÔÑàõ).
  • active hyperemia
    ´Éµ¿Àû Ç÷·ùÁõ°¡(ÒöÔÑîÜúì×µñòÊ¥)
  • active apperception
    ÀÚµ¿(Àû)Åë°¢(ÀÛ¿ë)(í»ÔÑîÜ÷ÖÊÆíÂéÄ).
  • active carbon
    Ȱ¼ºÅº(üÀàõ÷©).
  • active earth
    Ȱ¼ºÅä(Ì·ËÛ̬).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active exercise
    ÀÚµ¿¿îµ¿(í»ÔÑê¡ÔÑ).
  • active force generation test
    ±Ù·Â°Ë»ç
  • active glycine
    Ȱ¼º(üÀàõ)±Û¸®½Å.
  • active gradient shielding
    ´Éµ¿ °æ»ç Â÷Æó
  • active hydrogen
    Ȱ¼º¼ö¼Ò(¡­â©áÈ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active imagination
    Àû±ØÀû »ó»ó
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active incorporative mode
    Àû±ØÀû ÇÔÀÔ ¾ç½Ä
  • active marrow
    Àû°ñ¼ö.
  • active material
    Ȱ¼º¹°Áú(üÀàõÚªòõ).
  • active movement
    ´Éµ¿¿îµ¿(ÒöÔÑê¡ÔÑ)
  • active negativism
    Àû±Ø¼º °ÅÀýÁõ.
  • active oxygen
    Ȱ¼º»ê¼Ò(üÀàõß«áÈ).
  • active shielding
    ´Éµ¿ Â÷Æó
  • active shimming
    ´Éµ¿ º¸Á¤
  • active site
    Ȱ¼ºÀÚ¸®.
  • active spot
    Ȱ¼ºÁ¡(üÀàõïÇ).
  • active tension
    ´Éµ¿Àå·Â(ÒöÔÑíåæ³)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active concentration
    Ȱ¼º³óµµ(üÀàõÒØÓø)
  • active form
    Ȱ¼ºÇü(üÀàõû¡)
  • active formaldehyde
    Ȱ¼º(üÀàõ)Æ÷¸§¾Ëµ¥ÇÏÀ̵å
  • active formate
    Ȱ¼º(üÀàõ)Æ÷¸§»ê(ß«)
  • active formimino
    Ȱ¼º(üÀàõ) Æ÷¸§À̹̳ë
  • active fructose
    Ȱ¼º(üÀàõ)ÇÁ¶ôÅäÁî
  • active glycolaldehyde
    Ȱ¼º(üÀàõ)±Û¸®Äݾ˵¥ÇÏÀ̵å
  • active hydroxyethyl
    Ȱ¼º(üÀàõ)ÇÏÀ̵å·Ï½Ã¿¡Æ¿
  • active hydroxymethyl
    Ȱ¼º(üÀàõ)ÇÏÀ̵å·Ï½Ã¸ÞÆ¿
  • active immunity
    ´Éµ¿¸é¿ª(ÒöÔÑØóæ¹)
  • active iodine
    Ȱ¼º(üÀàõ)¿äµå
  • active mediated transport
    ´Éµ¿¸Å°³¼ö¼Û (ÒöÔÑØÚË¿âÃáê)
  • active methionine
    Ȱ¼º(üÀàõ)¸ÞŸÀÌ¿À´Ñ
  • active methyl
    Ȱ¼º(üÀàõ)¸ÞÆ¿
  • active patch
    Ȱ¼º(üÀàõ)ÆÖÄ¡
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AAROM active assertive range of motion; active-assisted range of motion
AS acetylstrophanthidin; acidified serum; acoustic schwannoma; acoustic stimulation; active sarcoidosis...
CPH Certificate in Public Health; chronic paroxysmal hemicrania; chronic persistent hepatitis; chronic p...
DRIP delirium and drugs-restricted mobility and retention-infection, inflammation and impaction-polyuria ...
HEMRI hereditary multifocal relapsing inflammation
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AS Active Sleep
A.S.I. Active Specific Immunotherapy
ACD Active compression decompression
ACA Active cutaneous anaphylaxis
AO Active oxygen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • purulent inflammation
    È­³ó¼º ¿°Áõ
  • simple inflammation
    ´Ü¼ø ¿°Áõ
  • specific inflammation
    ƯÀ̼º ¿°Áõ
  • sterile inflammation
    ¹«±Õ¼º ¿°Áõ
  • subacute inflammation
    ¾Æ±Þ¼º ¿°Áõ
  • ulcerative inflammation
    ±Ë¾ç¼º ¿°Áõ
  • active
    Ȱ¼º, Ȱµ¿¼º, ´Éµ¿¼º
    ÀÛ¿ë, Ȱµ¿, ÇàÀ§¸¦ Ư¡À¸·Î Çϸç, ¼öµ¿ÀûÀÌ ¾Æ´Ñ °Í.
  • active acupuncture locus
    Ȱµ¿¼º °æÇ÷ Á¡
  • active coefficient
    Ȱ¼ºµµ °è¼ö
    ¹°ÁúÀÇ ³óµµ°¡ ³·À» ¶§¿¡ ¹ÝÀÀ·ÂÀº ³óµµ¿¡ ºñ·ÊÇϴµ¥ ³óµµ°¡ ³ô¾ÆÁ³À» ¶§´Â ¹ÝÀÀ·ÂÀÌ °¨¼ÒµÇ°í, ³óµµ¿¡ Ȱµ¿°è¼ö¸¦ °öÇÑ °Í¿¡ ºñ·ÊÇØ¼­ ¹ÝÀÀ·ÂÀÌ ³ªÅ¸³­´Ù.
  • active eruption
    Ȱ¼º ¸ÍÃâ, ´Éµ¿Àû ¸ÍÃâ
    1. ¸Å¸ôµÇ¾î ÀÖ´ø Ä¡¾Æ°¡ »ý¸®ÀûÀ¸·Î ´ëÇÕÄ¡ÀÇ ±³ÇÕ¸é±îÁö ¸ÍÃâÇϰųª ¸ÍÃâµÈ Ä¡¾Æ°¡ ¸¶¸ðµÈ °í°æ¸¸Å­ º¸»óÇϱâ À§ÇØ ¸ÍÃâÇÏ´Â Çö»ó. 2. Ä¡¾Æ°¡ ±³ÇÕÁ¢ÃËÀ» ÀÌ·é ÈÄ, ±³ÇÕÆò¸é ¹æÇâÀ¸·Î ´Éµ¿Àû À̵¿À» º¸ÀÌ´Â °Í.
  • active exercise program
    Àû±ØÀû ¿îµ¿
  • active gradient shielding
    ´Éµ¿ °æ»çÂ÷Æó
  • active hydrogen
    Ȱ¼º ¼ö¼Ò
  • active immunity
    ´Éµ¿ ¸é¿ª
    Ç׿ø Àڱؿ¡ ¹ÝÀÀÇÏ¿© »ý»êµÈ Ç×ü³ª ¸é¿ª ¸²ÇÁ°è ¼¼Æ÷ÀÇ Á¸Àç·Î ÀÎÇÑ È¹µæ¸é¿ª. »ç¶÷¿¡ ´ëÇØ¼­ ¹é½ÅÀ̳ª µ¶¼ºÀ¸·Î ¸é¿ªÇÏ´Â °ÍÀ¸·Î ÀÚ½ÅÀÇ ¸öÀ¸·Î ¸é¿ªÀ» ¸¸µé¾î³»¹Ç·Î È¿°ú´Â ¿À·¡ Áö¼ÓµÈ´Ù.
  • active mandibular opening
    ´Éµ¿ ÇÏ¾Ç °³±¸
    ±æÇ×±Ù
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
pseudomembranous inflammation A form of exudative inflammation that involves mucous and serous membranes; relatively large quantities of fibrin in the exudate result in a rather tenacious membrane-like covering that is fairly adherent to the underlying acutely inflamed tissue; the pseudomembrane usually contains (in addition to the dense network of fibrin) varying quantities of plasma protein, degenerated and necrotic elements from the affected tissue, polymorphonuclear leukocytes, bacteria, etc.
(05 Mar 2000)
purulent inflammation An acute exudative inflammation in which the accumulation of polymorphonuclear leukocytes is sufficiently great that their enzymes cause liquefaction of the affected tissues, focally or diffusely; the purulent exudate is frequently termed pus, and consists of plasma and its constituents, end products of the enzymatic digestion of tissue, degenerated and necrotic cells and their debris, polymorphonuclear leukocytes and other white blood cells, the causal agent of the inflammation, etc.
Synonym: suppurative inflammation.
(05 Mar 2000)
serofibrinous inflammation Inflammation in which the exudate consists chiefly of serous fluid with an unusually large proportion of fibrin.
(05 Mar 2000)
serous inflammation An exudative inflammation in which the exudate is predominantly fluid (e.g., exuded from the blood vessels), with the protein, electrolytes, and other material contained therein; relatively few (if any) cells are observed.
(05 Mar 2000)
hyperplastic inflammation An inflammatory reaction in which the distinguishing feature is an actual increase in the number of tissue cells, especially the reticuloendothelial macrophages, in contrast to cells exuded from blood vessels; in addition, exudates of various types are likely to be observed in granulomas and other forms of proliferative inflammation, but the latter may occur without an exudate being formed (as in certain infections caused by virus).
Synonym: hyperplastic inflammation.
(05 Mar 2000)
necrotic inflammation Usually an acute inflammatory reaction in which the predominant histologic change is fairly rapid necrosis that occurs diffusely or extensively in relatively large foci throughout the affected tissue, frequently with only little or no evidence of cells in the exudate.
(05 Mar 2000)
subacute inflammation An inflammation that is intermediate in duration between that of an acute inflammation and that of a chronic inflammation, usually persisting longer than 3 or 4 weeks.
(05 Mar 2000)
suppurative inflammation An acute exudative inflammation in which the accumulation of polymorphonuclear leukocytes is sufficiently great that their enzymes cause liquefaction of the affected tissues, focally or diffusely; the purulent exudate is frequently termed pus, and consists of plasma and its constituents, end products of the enzymatic digestion of tissue, degenerated and necrotic cells and their debris, polymorphonuclear leukocytes and other white blood cells, the causal agent of the inflammation, etc.
Synonym: suppurative inflammation.
(05 Mar 2000)
degenerative inflammation A local reaction to injury, occasionally observed in the walls of blood vessels and in parenchymal cells of various organs in reacting to certain chemicals, viruses, and other intracellular agents; the response is characterised by degenerative changes in the cytoplasm and nucleus, frequently resulting in necrosis, but exudation (if any) is ordinarily observed only in the wall of the affected vessel, or in the interstices immediately adjacent to the affected vessel or parenchymal cells.
Synonym: degenerative inflammation.
(05 Mar 2000)
immune inflammation See: allergic reaction.
(05 Mar 2000)
inflammation <pathology> A localised protective response elicited by injury or destruction of tissues, which serves to destroy, dilute or wall off (sequester) both the injurious agent and the injured tissue.
It is characterised in the acute form by the classical signs of pain (dolor), heat (calor), redness (rubor), swelling (tumour) and loss of function (functio laesa).
Histologically, it involves a complex series of events, including dilatation of arterioles, capillaries and venules, with increased permeability and blood flow, exudation of fluids, including plasma proteins and leucocytic migration into the inflammatory focus.
Origin: L. Inflammatio, inflammare = to set on fire
(11 Jun 1998)
inflammation: gallium imaging <radiology> Pathophysiology: leakage of protein-bound Ga-67 into extracellular space secondary to increased capillary permeability, Ga-67 is preferentially bound to nonviable PMNs and macrophages, leukocyte incorporation (rich in lactoferrin), bacterial uptake (siderophores), inflammtory tissue stimulates lactoferrin production for chronic abdominal inflammation: 67% sensitivity; 64% specificity; 13% false negatives; 5% false positive, dose: 5 mCi; imaging: 24, 48, 72 hours, diffuse uptake in peritonitis, localised uptake in acute pyogenic abscess, phlegmon, acute cholecystitis, acute pancreatitis, acute gastritis, diverticulitis, inflammatory bowel disease, surgical wound, pyelonephritis, perinephric abscess see: gallium indications, gallium vs. Indium
(12 Dec 1998)
inflammation mediators The endogenous compounds that mediate inflammation (autacoids) and related exogenous compounds including the synthetic prostaglandins (prostaglandins, synthetic).
(12 Dec 1998)
interstitial inflammation Inflammation in which the inflammatory reaction occurs chiefly in the supportive fibrous connective tissue or stroma of an organ.
(05 Mar 2000)
exudative inflammation Inflammation in which the conspicuous or distinguishing feature is an exudate, which may be chiefly serous, serofibrinous, fibrinous, or mucous (e.g., relatively few cells are present), or may be characterised by relatively large numbers of neutrophils, eosinophils, lymphocytes, monocytes, or plasma cells, frequently with one or two types being predominant; it occurs not only as a separate and distinct pathologic process, but also frequently as a part of certain granulomatous inflammation's.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á